



PRESS RELEASE

MolMed: resignation of the Officer Responsible for the preparation of corporate financial reports

Milan (Italy), June 29th 2018 – MolMed S.p.A. announces that today Andrea Quaglino, resigned from his position as Officer Responsible for the preparation of corporate financial reports of the Company, effective from September 30th, 2018, to begin a new professional experience.

In order to allow operational continuity and a smooth transition for the Company, Andrea Quaglino will continue to serve as and maintain the responsibilities of Chief Financial Officer and Officer Responsible for the preparation of corporate financial reports of MolMed S.p.A. until the appointment of his successor, whose recruitment process will start soon.

Riccardo Palmisano, Chief Executive Officer of MolMed S.p.A., said: *“I would like to really thank Andrea for his relevant contribution to the growth of the Company during the five years he spent with us and I wish him all the success that he deserves in his career”*.

On the basis of available information, Andrea Quaglino does not hold any shares of MolMed S.p.A.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed's pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.



PRESS RELEASE

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Marcella Ruggiero

Press agent

SEC Relazioni Pubbliche e Istituzionali s.r.l.

+39 02 6249991

+39 335 214241

ruggiero@secrp.com